Table 3

Clinical efficacy of chemotherapy: single agent versus combination

Agent (Ref.)aNo. of patientsResponseMed TTPMed Surv
VP-16 (21)24Obj-8%NR6.8 mths
E+ VP-16 (5)42Obj-50% PSA-52%NRNR
Vinb (19)39Obj-20%6.2 mthsNR
E + Vinb (22)36Obj-28% PSA-61%3.5 mths10.6 mths
Vinb (23)98Obj-6% PSA-3%2.2 mths9.2 mths
E + Vinb (23)95Obj-20% PSA-25%3.7 mths11.9 mths
Tax (20)23Obj-4.3%9 mths9 mths
E + Tax (6)36Obj-44% PSA-53%5 mths15.3 mths
  • a Ref, references; E, estramustine; VP-16, etoposide; Vinb, vinblastine; Tax, paclitaxel; Med, median; TTP, time to progression; Surv, survival; Obj, objective; PSA response >50% decrease in PSA maintained for at least three consecutive values at least 2 weeks apart; mths, months; NR, not reported.